Syndicated Research Studies

COPD and Asthma Therapeutics Market Overview The global COPD and asthma therapeutics market was valued at USD 92.30 billion in 2024 and is projected to reach USD 155.25 billion by 2030, growing at a CAGR of 9.18% between 2025 and 2030. The market is being driven by the rising prevalence of chronic respiratory conditions, fueled by increasing pollution levels, tobacco usage, and an aging global population. These factors are contributing to heightened demand for bronchodilators, corticosteroids, and combination therapies. According to the Global Initiative for Asthma (GINA), over 262 million people worldwide were affected by asthma in 2022. Additionally, the World Health Organization (WHO) reported that COPD ranked as the third leading cause of death globally. The growing elderly population, combined with rising emissions from vehicles and industries, continues to be a major contributor to the surge in COPD and asthma cases. Air quality degradation—especially near industrial zo...

The global COPD and asthma therapeutics market size is anticipated to reach USD 155.25 billion by 2030 and is expected to expand at a CAGR of 9.18% during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is propelled by a rising prevalence of respiratory disorders worldwide. Urbanization, increasing exposure to air pollutants, tobacco smoke, and occupational hazards have significantly contributed to the surge in cases of asthma and chronic obstructive pulmonary disease. According to the World Health Organization, COPD is projected to become the third leading cause of death globally by 2030, underscoring the urgent need for effective treatment solutions. This growing patient pool has intensified demand for advanced therapeutics, including inhalers, nebulizers, and biologic drugs, thereby driving market expansion. Technological advancements in drug delivery systems have further catalyzed market growth. The development of smart inhaler...